跳至主要内容
临床试验/NCT01279434
NCT01279434撤回不适用

Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial

Institute of Liver and Biliary Sciences, India1 个研究点 分布在 1 个国家开始时间: 2012年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
Improvement in hepatocyte injury and fibrosis (NAFLD Activity Score [NAS score])

研究概览

简要总结

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of hepatic pathology, ranging from simple steatosis, steatohepatitis, to cirrhosis. Nonalcoholic steatohepatitis (NASH) is a more advanced form of disease where steatosis is accompanied by hepatocyte injury as well as infiltration of inflammatory cells. Since, both vitamin E and PTX has been found to improve NASH when used alone, a combination of these two should be expected to give better results because of targeting two different pathogenetic mechanisms (cytokines amplification and oxidative stress) in NASH patients. This will be open labelled, prospective, randomized study. The diagnosis of NAFLD will be made on the basis of Ultrasonographic findings suggestive of fatty liver and presence of insulin resistance or features of metabolic syndrome. Subsequently histologic confirmation of the diagnosis of NASH will be made in all cases.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of NAFLD by ultrasonographic
  • Presence of Insulin resistance
  • Histological confirmation of NASH
  • Increased transaminases (>1.5 upper limit normal [ULN])

排除标准

  • Patients with alcohol > 20g/ day
  • Other known liver disease
  • Medications known to induce fatty liver

研究组 & 干预措施

Vitamin E plus Pentoxiphyllin

Experimental

干预措施: Vitamin E plus Pentoxiphyllin (Drug)

Vitamin E

Active Comparator

干预措施: Vitamin E (Drug)

结局指标

主要结局

Improvement in hepatocyte injury and fibrosis (NAFLD Activity Score [NAS score])

时间窗: Baseline and 1 year

次要结局

  • Normalization of serum transaminases levels(Baseline and 1 year)
  • Reduction in serum levels of proinflammatory cytokines (TNF-α and IL-6) and Malondialdehyde (MDA).(Baseline and 1 year)
  • Improvement in HOMA-IR(Baseline and 1 year)
  • No worsening of fibrosis(Baseline and 1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验